Ipamorelin vs GHRP-2

Side-by-side comparison of Ipamorelin, GHRP-2 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Ipamorelin Ipamorelin (Selective GHRP) Growth Hormone GHRP-2 Growth Hormone Releasing Peptide-2 Growth Hormone
Basics
Molecular type Growth Hormone Releasing Peptide (GHRP)Growth Hormone Releasing Peptide (GHRP)
Amino acids 56
Molecular weight 711.9 Da817.9 Da
Half-life ~2 hours~1–2 hours
Route(s) Subcutaneous, IntramuscularSubcutaneous, Intramuscular, Intranasal
Mechanism & Research
Primary mechanism Ipamorelin activates growth hormone secretagogue receptors (GHSR-1a) in the pituitary, triggering pulsatile GH release. Unlike first-generation GHRPs (GHRP-6, GHRP-2), ipamorelin's selectivity for GHSR-1a is high enough … GHRP-2 activates the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus. Hypothalamic activation leads to reduced somatostatin tone (the GH release inhibitor), while pituitary activation directly triggers GH se…
Research status Research Compound Research Compound
Evidence summary Ipamorelin was among the first highly selective GHRPs to enter research. Phase 1 trials confirmed its clean hormonal profile. It remains a reference GHRP in comparative studies and is widely used as the GHRP component in… GHRP-2 has been extensively studied in humans including as a diagnostic tool for GH deficiency assessment. Its well-characterised dose-response relationship makes it a reference compound in the GHRP class.
Protocol & Dosing
Typical dose 100–300 mcg per injection100–200 mcg per injection
Frequency 2–3x daily (or 1x at bedtime)2–3x daily
Duration 8–12 weeks on, 4 weeks off8–12 weeks
Timing Fasted state or 2+ hours post-meal for maximum GH response; bedtime dosing utilises natural nocturnal GH pulseFasted state; 2+ hours post-meal
Safety
Common side effects
  • Water retention (mild)
  • Tingling/numbness (extremities)
  • Headache (transient)
  • Injection site redness
  • Cortisol elevation (dose-dependent)
  • Prolactin increase (transient)
  • Increased appetite
  • Water retention
Contraindications
  • Active malignancy
  • Uncontrolled diabetes
  • Pregnancy
  • Active malignancy
  • Hypothyroidism
  • Pregnancy
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides CJC-1295, GHRP-2, Sermorelin, Tesamorelin Ipamorelin, CJC-1295, GHRP-6, Hexarelin
Full profile Read full Ipamorelin profile → Read full GHRP-2 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.